ABT‐199, a selective targeting inhibitor of BCL‐2, has emerged as a promising treatment strategy for some B‐cell malignancies such as CLL and MCL (mantle cell lymphoma). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.